Production (Stage)
Xilio Therapeutics, Inc.
XLO
$0.8838
-$0.0132-1.47%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 9.27M | 6.34M | 4.62M | 2.36M | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.27M | 6.34M | 4.62M | 2.36M | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 9.27M | 6.34M | 4.62M | 2.36M | -- |
| SG&A Expenses | 27.15M | 24.78M | 24.66M | 24.66M | 25.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 66.23M | 65.99M | 68.77M | 69.06M | 72.15M |
| Operating Income | -56.96M | -59.65M | -64.15M | -66.70M | -72.15M |
| Income Before Tax | -54.30M | -58.24M | -62.80M | -65.53M | -70.96M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -54.30 | -58.24 | -62.80 | -65.53 | -70.96 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -54.30M | -58.24M | -62.80M | -65.53M | -70.96M |
| EBIT | -56.96M | -59.65M | -64.15M | -66.70M | -72.15M |
| EBITDA | -55.26M | -58.00M | -62.43M | -64.91M | -70.30M |
| EPS Basic | -0.92 | -1.36 | -1.79 | -2.18 | -2.57 |
| Normalized Basic EPS | -0.57 | -0.83 | -1.10 | -1.34 | -1.59 |
| EPS Diluted | -0.92 | -1.36 | -1.79 | -2.18 | -2.57 |
| Normalized Diluted EPS | -0.57 | -0.83 | -1.10 | -1.34 | -1.59 |
| Average Basic Shares Outstanding | 246.79M | 200.01M | 162.89M | 126.95M | 110.46M |
| Average Diluted Shares Outstanding | 246.79M | 200.01M | 162.89M | 126.95M | 110.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |